Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis.
Cortical excitability
Disease-modifying therapies
Multiple sclerosis
TMS
Upper extremity impairment
progressive
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
30
11
2021
accepted:
29
03
2022
revised:
28
03
2022
pubmed:
15
4
2022
medline:
12
8
2022
entrez:
14
4
2022
Statut:
ppublish
Résumé
Hand dexterity impairment is a key feature of disability in people with primary progressive multiple sclerosis (PPMS). So far, ocrelizumab, a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, is the only therapy approved for PPMS and recent analysis reported its ability to reduce the risk of upper limb disability progression. However, the neural mechanisms underlying hand impairment in PPMS and the brain networks behind the effect of ocrelizumab on manual dexterity are not fully understood. Main aims of our study were: (i) to investigate neurophysiological and behavioural correlates of hand function impairment in subjects with PPMS, and (ii) to use neurophysiologic and behavioural measures to track the effects of ocrelizumab therapy on manual dexterity. Seventeen PPMS patients and 17 healthy-controls underwent routine neurophysiological protocols assessing the integrity of cortico-spinal and somatosensory pathways and advanced transcranial magnetic stimulation (TMS) protocols evaluating inhibitory (short and long interval intracortical inhibition, short-latency afferent inhibition) and facilitatory (motor thresholds, intracortical facilitation, short-interval intracortical facilitation) circuits in the primary motor cortex. All subjects also underwent behavioural analysis of hand dexterity by means of nine-hole peg test and finger movement analysis, and hand strength with handgrip and three-point pinch test. Neurophysiological and clinical assessments of hand functionality were also performed after 1 year of ocrelizumab therapy. At baseline PPMS patients displayed a significant impairment of hand dexterity and strength compared to healthy controls (all p < 0.03). Neurophysiological study disclosed prolonged latencies of standard somatosensory and motor evoked potentials (all p < 0.025) and an overall reduction of intracortical excitability at TMS protocols, involving both excitatory and inhibitory circuits. Importantly, hand dexterity impairment, indexed by delayed 9HPT, correlated with TMS protocols investigating cortical sensorimotor integration (short-latency afferent inhibition, SAI), p = 0.009. Both parameters, 9HPT (p = 0.01) and SAI (p = 0.01), displayed a significant improvement after 1 year of therapy with ocrelizumab. Intracortical sensorimotor networks are involved in hand dexterity dysfunction of PPMS. Ocrelizumab therapy displays a beneficial effect on hand dexterity impairment most likely through intracortical networks implicated in fast sensorimotor integration.
Sections du résumé
BACKGROUND
BACKGROUND
Hand dexterity impairment is a key feature of disability in people with primary progressive multiple sclerosis (PPMS). So far, ocrelizumab, a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, is the only therapy approved for PPMS and recent analysis reported its ability to reduce the risk of upper limb disability progression. However, the neural mechanisms underlying hand impairment in PPMS and the brain networks behind the effect of ocrelizumab on manual dexterity are not fully understood.
OBJECTIVE
OBJECTIVE
Main aims of our study were: (i) to investigate neurophysiological and behavioural correlates of hand function impairment in subjects with PPMS, and (ii) to use neurophysiologic and behavioural measures to track the effects of ocrelizumab therapy on manual dexterity.
METHODS
METHODS
Seventeen PPMS patients and 17 healthy-controls underwent routine neurophysiological protocols assessing the integrity of cortico-spinal and somatosensory pathways and advanced transcranial magnetic stimulation (TMS) protocols evaluating inhibitory (short and long interval intracortical inhibition, short-latency afferent inhibition) and facilitatory (motor thresholds, intracortical facilitation, short-interval intracortical facilitation) circuits in the primary motor cortex. All subjects also underwent behavioural analysis of hand dexterity by means of nine-hole peg test and finger movement analysis, and hand strength with handgrip and three-point pinch test. Neurophysiological and clinical assessments of hand functionality were also performed after 1 year of ocrelizumab therapy.
RESULTS
RESULTS
At baseline PPMS patients displayed a significant impairment of hand dexterity and strength compared to healthy controls (all p < 0.03). Neurophysiological study disclosed prolonged latencies of standard somatosensory and motor evoked potentials (all p < 0.025) and an overall reduction of intracortical excitability at TMS protocols, involving both excitatory and inhibitory circuits. Importantly, hand dexterity impairment, indexed by delayed 9HPT, correlated with TMS protocols investigating cortical sensorimotor integration (short-latency afferent inhibition, SAI), p = 0.009. Both parameters, 9HPT (p = 0.01) and SAI (p = 0.01), displayed a significant improvement after 1 year of therapy with ocrelizumab.
CONCLUSION
CONCLUSIONS
Intracortical sensorimotor networks are involved in hand dexterity dysfunction of PPMS. Ocrelizumab therapy displays a beneficial effect on hand dexterity impairment most likely through intracortical networks implicated in fast sensorimotor integration.
Identifiants
pubmed: 35419681
doi: 10.1007/s00415-022-11114-x
pii: 10.1007/s00415-022-11114-x
pmc: PMC9363320
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
ocrelizumab
A10SJL62JY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4791-4801Informations de copyright
© 2022. The Author(s).
Références
Holper L, Coenen M, Weise A et al (2010) Characterization of functioning in multiple sclerosis using the ICF. J Neurol 257:103–113. https://doi.org/10.1007/s00415-009-5282-4
doi: 10.1007/s00415-009-5282-4
pubmed: 19756827
Poole J, Nakamoto T, McNulty T et al (2010) Dexterity, visual perception, and activities of daily living in persons with multiple sclerosis. Occup Ther Heal Care 24:159–170. https://doi.org/10.3109/07380571003681202
doi: 10.3109/07380571003681202
Yozbatiran N, Baskurt F, Baskurt Z et al (2006) Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients. J Neurol Sci 246:117–122. https://doi.org/10.1016/j.jns.2006.02.018
doi: 10.1016/j.jns.2006.02.018
pubmed: 16678208
Feys P, Lamers I, Francis G et al (2017) The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler J 23:711–720. https://doi.org/10.1177/1352458517690824
doi: 10.1177/1352458517690824
Bonzano L, Sormani MP, Tacchino A et al (2013) Quantitative assessment of finger motor impairment in multiple sclerosis. PLoS One 8:1–7. https://doi.org/10.1371/journal.pone.0065225
doi: 10.1371/journal.pone.0065225
Pisa M, Chieffo R, Giordano A et al (2020) Upper limb motor evoked potentials as outcome measure in progressive multiple sclerosis. Clin Neurophysiol 131:401–405. https://doi.org/10.1016/j.clinph.2019.11.024
doi: 10.1016/j.clinph.2019.11.024
pubmed: 31869704
Hardmeier M, Leocani L, Fuhr P (2017) A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. Mult Scler 23:1309–1319. https://doi.org/10.1177/1352458517707265
doi: 10.1177/1352458517707265
pubmed: 28480798
pmcid: 5564950
Pisa M, Chieffo R, Congiu M et al (2021) Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis. Mult Scler J 27:1222–1229. https://doi.org/10.1177/1352458520960374
doi: 10.1177/1352458520960374
Dubbioso R, Manganelli F, Siebner HR, Di Lazzaro V (2019) Fast intracortical sensory-motor integration: a window into the pathophysiology of Parkinson’s Disease. Front Hum Neurosci 13:111
doi: 10.3389/fnhum.2019.00111
Dubbioso R, Raffin E, Karabanov A et al (2017) Centre-surround organization of fast sensorimotor integration in human motor hand area. Neuroimage 158:37–47. https://doi.org/10.1016/j.neuroimage.2017.06.063
doi: 10.1016/j.neuroimage.2017.06.063
pubmed: 28669907
Gelfand JM, Cree BAC, Hauser SL (2017) Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics 14:835–841. https://doi.org/10.1007/s13311-017-0557-4
doi: 10.1007/s13311-017-0557-4
pubmed: 28695471
pmcid: 5722762
Montalban X, Hauser SL, Kappos L et al (2017) ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376:209–220. https://doi.org/10.1056/NEJMoa1606468
doi: 10.1056/NEJMoa1606468
pubmed: 28002688
Fox E, Markowitz C, Applebee A et al (2018) ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Mult Scler J 24:1862–1870. https://doi.org/10.1177/1352458518808189
doi: 10.1177/1352458518808189
Hanajima R, Ugawa Y, Terao Y et al (1998) Paired-pulse magnetic stimulation of the human motor cortex: differences among I waves. J Physiol 509:607–618. https://doi.org/10.1111/j.1469-7793.1998.607bn.x
doi: 10.1111/j.1469-7793.1998.607bn.x
pubmed: 9575308
pmcid: 2230978
Hanajima R, Ugawa Y, Terao Y et al (2002) Mechanisms of intracortical I-wave facilitation elicited with paired-pulse magnetic stimulation in humans. J Physiol 538:253–261. https://doi.org/10.1113/jphysiol.2001.013094
doi: 10.1113/jphysiol.2001.013094
pubmed: 11773332
pmcid: 2290031
Ziemann U, Tergau F, Wischer S et al (1998) Pharmacological control of facilitatory I-wave interaction in the human motor cortex. A paired transcranial magnetic stimulation study. Electroencephalogr Clin Neurophysiol - Electromyogr Mot Control 109:321–330. https://doi.org/10.1016/S0924-980X(98)00023-X
doi: 10.1016/S0924-980X(98)00023-X
Nakamura H, Kitagawa H, Kawaguchi Y, Tsuji H (1997) Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. J Physiol 498(Pt 3):817–823
doi: 10.1113/jphysiol.1997.sp021905
Tokimura H, Di Lazzaro V, Tokimura Y et al (2000) Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol 523:503–513. https://doi.org/10.1111/j.1469-7793.2000.t01-1-00503.x
doi: 10.1111/j.1469-7793.2000.t01-1-00503.x
pubmed: 10699092
pmcid: 2269813
Dubbioso R, Striano P, Tomasevic L et al (2022) Abnormal sensorimotor cortex and thalamo-cortical networks in familial adult myoclonic epilepsy type 2: pathophysiology and diagnostic implications. Brain Commun 4:1–15. https://doi.org/10.1093/braincomms/fcac037
doi: 10.1093/braincomms/fcac037
Dubbioso R, Pellegrino G, Antenora A et al (2015) The effect of cerebellar degeneration on human sensori-motor plasticity. Brain Stimul 8:1144–1150. https://doi.org/10.1016/j.brs.2015.05.012
doi: 10.1016/j.brs.2015.05.012
pubmed: 26140957
Cruccu G, Aminoff MJ, Curio G et al (2008) Recommendations for the clinical use of somatosensory-evoked potentials. Clin Neurophysiol 119:1705–1719. https://doi.org/10.1016/j.clinph.2008.03.016
doi: 10.1016/j.clinph.2008.03.016
pubmed: 18486546
Ziemann U, Reis J, Schwenkreis P et al (2015) TMS and drugs revisited 2014. Clin Neurophysiol 126:1847–1868. https://doi.org/10.1016/j.clinph.2014.08.028
doi: 10.1016/j.clinph.2014.08.028
pubmed: 25534482
Inghilleri M, Conte A, Frasca V et al (2006) Altered response to rTMS in patients with Alzheimer’s disease. Clin Neurophysiol 117:103–109. https://doi.org/10.1016/j.clinph.2005.09.016
doi: 10.1016/j.clinph.2005.09.016
pubmed: 16364684
Vucic S, Burke T, Lenton K et al (2012) Cortical dysfunction underlies disability in multiple sclerosis. Mult Scler J 18:425–432. https://doi.org/10.1177/1352458511424308
doi: 10.1177/1352458511424308
Nicoletti CG, Monteleone F, Marfia GA et al (2020) Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis. Mult Scler J 26:304–311. https://doi.org/10.1177/1352458519828294
doi: 10.1177/1352458519828294
Ayache SS, Créange A, Farhat WH et al (2015) Cortical excitability changes over time in progressive multiple sclerosis. Funct Neurol 30:257–263
pubmed: 26727704
Dubbioso R, Madsen KH, Thielscher A, Siebner HR (2021) The myelin content of the human precentral hand knob reflects interindividual differences in manual motor control at the physiological and behavioral level. J Neurosci 41:3163–3179. https://doi.org/10.1523/JNEUROSCI.0390-20.2021
doi: 10.1523/JNEUROSCI.0390-20.2021
pubmed: 33653698
pmcid: 8026359
Di Lazzaro V, Ziemann U (2013) The contribution of transcranial magnetic stimulation in the functional evaluation of microcircuits in human motor cortex. Front Neural Circuits 7:1–9. https://doi.org/10.3389/fncir.2013.00018
doi: 10.3389/fncir.2013.00018
MacKenzie-Graham A, Kurth F, Itoh Y et al (2016) Disability-specific atlases of gray matter loss in relapsing-remitting multiple sclerosis. JAMA Neurol 73:944–953. https://doi.org/10.1001/jamaneurol.2016.0966
doi: 10.1001/jamaneurol.2016.0966
pubmed: 27294295
pmcid: 6415681
Colato E, Stutters J, Tur C et al (2021) Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. J Neurol Neurosurg Psychiatry 92:995–1006. https://doi.org/10.1136/jnnp-2020-325610
doi: 10.1136/jnnp-2020-325610
pubmed: 33879535
Silva BA, Miglietta E, Ferrari CC (2021) Insights into the role of B cells in the cortical pathology of Multiple sclerosis: evidence from animal models and patients. Mult Scler Relat Disord. https://doi.org/10.1016/j.msard.2021.102845
doi: 10.1016/j.msard.2021.102845
pubmed: 35216784
pmcid: 7937038